Showing 2 of 10 years of data. Sign up free for 5 years of history.
View Plans2-year trend showing gross, operating, and net profit margins
Dr. Reddy's Laboratories Ltd.'s net profit margin of 11.9% in FY2026 reflects moderate profitability, with operating margin at 16.4% and gross margin at 65.1%.
In FY 2026, Dr. Reddy's Laboratories Ltd. posted a gross margin of 65.1%, an operating margin of 16.4%, a net margin of 11.9%. Gross Margin = (Revenue - COGS) / Revenue; Operating Margin = EBIT / Revenue; Net Margin = Net Income / Revenue. Typical healthy ranges: Gross 20-40%, Operating 10-20%, Net 5-10%+. Consistent or improving margins indicate strong competitive positioning.
2-year trend showing revenue, gross profit, and net profit
Dr. Reddy's Laboratories Ltd.'s revenue grew 3.9% to 350.59B in FY2026, but net profit declined 27.4% to 41.58B — indicating margin compression.
In FY 2026, Dr. Reddy's Laboratories Ltd.'s revenue grew by 3.9% year-over-year. Revenue is total income from operations. Gross Profit is revenue minus cost of goods. Net Profit is the bottom line after all expenses. Consistent growth across all three signals a healthy, expanding business.
2-year trend showing shareholder returns
Dr. Reddy's Laboratories Ltd.'s ROE of 10.9% in FY2026 indicates moderate shareholder returns.
In FY 2026, Dr. Reddy's Laboratories Ltd. reported an ROE of 10.9%. ROE = (Net Income / Shareholders' Equity) x 100. Measures how efficiently the company turns equity into profit. Above 15% is generally strong; above 25% is excellent. Very high ROE may signal high leverage — check alongside debt levels.
2-year trend comparing profitability with cash generation
Dr. Reddy's Laboratories Ltd.'s FCF/NI ratio of 0.80x in FY2026 indicates reasonable cash generation relative to profits.
In FY 2026, Dr. Reddy's Laboratories Ltd.'s free cash flow trailed net income. Free Cash Flow = Operating Cash Flow - Capital Expenditure. When FCF exceeds net income, it suggests high-quality, cash-backed earnings. Persistent gaps may indicate aggressive accounting or heavy capex needs.
2-year trend comparing profitability with cash from operations
Dr. Reddy's Laboratories Ltd.'s OCF/NI ratio of 1.36x in FY2026 indicates strong cash collection and working capital efficiency.
In FY 2026, Dr. Reddy's Laboratories Ltd.'s operating cash flow exceeded net income. Operating Cash Flow is the actual cash from core operations. OCF exceeding net income signals strong cash collection. OCF trailing net income may indicate aggressive revenue recognition or working capital issues.
Measure a company's financial leverage, liquidity, and ability to meet financial obligations.
2-year trend showing short-term liquidity position
Dr. Reddy's Laboratories Ltd.'s current ratio of 1.80x in FY2026 indicates healthy short-term liquidity.
In FY 2026, Dr. Reddy's Laboratories Ltd. reported a current ratio of 1.80. Current Ratio = Current Assets / Current Liabilities. Measures short-term liquidity. A ratio of 1.5-3.0 is generally healthy; below 1.0 signals liquidity risk; above 3.0 may indicate underutilized assets.
2-year trend showing ability to service debt
Dr. Reddy's Laboratories Ltd.'s interest coverage ratio of 15.4x in FY2026 indicates comfortable debt servicing capacity.
In FY 2026, Dr. Reddy's Laboratories Ltd. reported an interest coverage ratio of 15.4x. Interest Coverage = EBIT / Interest Expense. Shows how many times operating profit covers interest payments. Above 5x is comfortable; below 1.5x signals potential difficulty servicing debt.
2-year trend showing financial leverage and capital structure
Dr. Reddy's Laboratories Ltd.'s debt-to-equity ratio of 0.20x in FY2026 reflects a conservative, low-leverage capital structure.
In FY 2026, Dr. Reddy's Laboratories Ltd. reported a debt-to-equity ratio of 0.20. Debt-to-Equity = Total Debt / Total Equity. Below 1.0 is conservative; 1.0-2.0 is moderate; above 2.0 indicates higher financial risk. Capital-intensive industries naturally carry higher ratios.
2-year trend showing total debt with year-over-year changes
Dr. Reddy's Laboratories Ltd.'s debt increased 65.4% YoY in FY2026 — rising leverage demands close monitoring.
In FY 2026, Dr. Reddy's Laboratories Ltd.'s total debt increased by 65.4% year-over-year. Total Debt includes short-term debt, long-term loans, debentures, and capital leases. YoY changes (shown as percentages) reveal whether the company is leveraging up or deleveraging.
Year-over-year change in diluted shares outstanding
Dr. Reddy's Laboratories Ltd.'s diluted shares decreased 0.1% YoY in FY2026, indicating shareholder-friendly buybacks.
Over 2 years (FY2025–FY2026), diluted shares decreased 0.1% from 834.18M to 833.33M, reflecting long-term shareholder value creation.
In FY 2026, Dr. Reddy's Laboratories Ltd.'s diluted shares decreased by 0.1% year-over-year. Diluted Shares accounts for stock options, warrants, and convertibles. Positive YoY change means dilution (red); negative means buybacks (green). Consistent dilution above 5% annually is a red flag.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2026